Full text
Earnings transcript
Read the complete earnings call transcript.
4507
4507.T
Shionogi & Co., Ltd.
$2744.5
-24.5
(-0.88%)
| Exchange: | JPX |
| Market Cap: | 2.336T |
| Shares Outstanding: | 904.434M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Drug Manufacturers – Specialty & GenericView industry performance | |||||
| CEO: | Isao Teshirogi | |||||
| Full Time Employees: | 6223 | |||||
| Address: |
| |||||
| Website: | https://www.shionogi.com |
Shionogi & Co., Ltd., an Osaka, Japan-based pharmaceutical company established in 1878, focuses on the discovery, development, production, and commercialization of medicines, diagnostic tools, and medical devices primarily within Japan. The company, known as Shionogi Shoten Co., Ltd. until its rebranding in 1943, maintains a comprehensive portfolio. Its marketed products include Fetroja, an agent for multidrug-resistant gram-negative bacterial infections; Xofluza, an antiviral treatment for influenza; and Tivicay, utilized in HIV therapy. Shionogi’s extensive pipeline features investigational therapies such as Symproic for opioid-induced constipation; S-120083 for inflammatory pain and S-010887 for neuropathic pain; S-117957 for insomnia; sivopixant, addressing neuropathic pain, sleep apnea syndrome, and persistent chronic cough; S-637880 for neuropathic low back pain; Zuranolone for depression; SDT-001 for attention-deficit/hyperactivity disorder; BPN14770 for Fragile X syndrome and Alzheimer’s disease; and S-237648 and S-309309 for obesity. Further development initiatives encompass ADR-001 for decompensated liver cirrhosis; S-723595 for NASH; various oncology candidates including S-588410 for esophageal and bladder cancer, S-488210 for head and neck squamous cell carcinoma, S-588210 for solid tumors, S-222611 for malignant tumors, and S-531011 for solid tumors; S-770108 for idiopathic pulmonary fibrosis; SR-0379 for cutaneous ulcers; S-005151 for stroke and epidermolysis bullosa; S-0373 for spinocerebellar ataxia; and multiple compounds targeting COVID-19, such as S-600918, S-217622, and S-555739 for mitigating disease progression. Additionally, the firm offers antibody test kits for COVID-19. Shionogi fosters strategic alliances, including collaborations with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University, aimed at advancing antimalarial drug research.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 438,268,000 | 499,677,000 | 499,677,000 |
| Gross Profit | 374,442,000 | 411,128,000 | 411,128,000 |
| EBITDA | 180,257,000 | 274,489,000 | 274,489,000 |
| Operating Income | 159,778,000 | 161,380,000 | 161,380,000 |
| Net Income | 170,435,000 | 205,160,000 | 205,160,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Total Assets | 1,416,918,000 | 1,535,349,000 | 2,576,870,000 |
| Total Liabilities | 164,354,000 | 172,850,000 | 890,662,000 |
| Total Stockholders Equity | 1,235,326,000 | 1,361,924,000 | 1,685,215,000 |
| Total Debt | 11,620,000 | 21,882,000 | 684,394,000 |
| Cash and Cash Equivalents | 358,090,000 | 374,795,000 | 711,397,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Operating Cash Flow | 154,284,000 | 195,460,000 | 213,572,000 |
| Capital Expenditure | -12,693,000 | -17,126,000 | -14,464,000 |
| Free Cash Flow | 141,591,000 | 178,334,000 | 199,108,000 |
| Net Income | 162,030,000 | 170,434,000 | 205,160,000 |
| Net Change in Cash | 48,866,000 | 16,705,000 | 336,602,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2031 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 699,070,672.993 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 776,106,346.502 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 731,151,000 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 211,392,676.383 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 236,709,689.264 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 221,935,559.700 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 148,798,708.800 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 170,412,644.497 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 157,799,502.185 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 164,339,537.331 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 182,449,304.243 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 171,881,072.546 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 185.400 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 200.220 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 174.820 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 4 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 5 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about 4507.T valuation
Is Shionogi & Co., Ltd. (4507.T) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Shionogi & Co., Ltd. (4507.T) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is 4507.T a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 4507.T trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is 4507.T’s P/E ratio?
You can see 4507.T’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for 4507.T?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is 4507.T a good long-term investment?
Whether 4507.T fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
4507.T
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.88
Trading Metrics:
| Open: | 2757.5 | Previous Close: | 2769 | |
| Day Low: | 2734 | Day High: | 2778 | |
| Year Low: | 2392.5 | Year High: | 3758 | |
| Price Avg 50: | 2877.36 | Price Avg 200: | 3061.47 | |
| Volume: | 3.306M | Average Volume: | 2.754M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
